Healthcare Industry News: Daxor
News Release - November 20, 2006
Daxor Announces Allegheny General Hospital of Pittsburgh, PA Acquires Blood Volume Analyzer BVA-100
NEW YORK--(HSMN NewsFeed)--Daxor Corporation (AMEX:DXR ), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Allegheny General Hospital of Pittsburgh, Pennsylvania.Founded in 1885 on Pittsburgh's historic North Side, Allegheny General Hospital has earned an international reputation for excellence and innovation. Serving Pittsburgh and the surrounding five-state area, the 829-bed academic health center has been recognized over the past eight years by U.S. News & World Report magazine as one of "America's Best Hospitals" and lauded as one of America's top 25 medical centers by the AARP's Modern Maturity magazine.
Daxor's BVA-100 will be located within Allegheny's Nuclear Cardiology Department. Dr. Srinivas Murali, Allegheny's Medical Director of the Gerald E. McGinnis Cardiovascular Institute and Division of Cardiology Director said that, "By directly measuring a patient's blood volume derangement and then treating the derangement versus our current surrogate assessments may prove to provide better outcomes for our patients." Dr. Murali, recognized as one of the "Best Doctors" in cardiovascular disease by Pittsburgh Magazine, recipient of the "Most Outstanding Physician" award from the Transplant Recipients International Organization, and honored as one of the "Best Heart Failure Specialists" by Business Week also noted that, "I see many patients with various degrees of blood volume problems. By utilizing a diagnostic tool that actually measures blood volume, I expect to be able to apply a more precise course of treatment to correct volume derangements."
A recent scientific report utilizing Daxor's BVA-100 presented during this year's Heart Failure Society Meeting detailed that patients with right-sided heart failure often have a reduction in red cell volume and a compensatory increase in plasma volume. This study demonstrated that by measuring the blood volume a clinician can distinguish between patients who have "true anemia" versus someone who has a normal red cell volume but too much plasma, which is called "hemodiluted anemia". Treatment for true anemia versus hemodiluted anemia is very different.
Daxor Corporation manufactures and markets the BVA-100, a FDA approved, semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, a single use radiopharmaceutical diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit www.Daxor.com.
Source: Daxor
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!